Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, New Zealand.
Drugs Aging. 2013 Jan;30(1):51-8. doi: 10.1007/s40266-012-0041-0.
In the EU, once-daily memantine 20 mg (Axura(®), Ebixa(®)) is an option for the management of patients with moderate to severe Alzheimer's disease (AD). In pooled clinical trials and studies in the clinical practice setting, memantine 20 mg/day improved cognition, functional ability and behavioural symptoms in this patient population. The beneficial effects of memantine are associated with delays in the need for full-time care, which were predicted to result in cost savings relative to standard care in recent cost-utility analyses in patients with moderate to severe AD conducted in EU countries. Memantine is well tolerated, with an adverse event profile that is similar to that with placebo.
在欧盟，每日一次给予 20 毫克美金刚（Axura(®)，Ebixa(®)）是治疗中重度阿尔茨海默病（AD）患者的一种选择。在汇总的临床试验和临床实践研究中，每日 20 毫克美金刚可改善该患者人群的认知功能、功能能力和行为症状。美金刚的有益作用与需要全职护理的时间延迟相关，最近在欧盟国家进行的中重度 AD 患者成本效用分析预测，与标准护理相比，这将导致成本节省。美金刚具有良好的耐受性，其不良事件谱与安慰剂相似。
